市场调查报告书
商品编码
1209806
全球血型市场:到 2028 年的预测——按产品、技术、测试类型、最终用户和地区分析Blood Group Typing Market Forecasts to 2028 - Global Analysis By Product, Techniques, Test Type, End User and By Geography |
根据 Stratistics MRC 的数据,2022 年全球血型市场规模将达到 18 亿美元,预计到 2028 年将达到 34.7 亿美元,预测期内復合年增长率为 11.5%。
血型测试是一种确定一个人的血型的方法。进行血型鑑定是为了安全地献血和输血。它还可以在红细胞表面寻找称为 Rh 因子的物质。血型在输血和献血中起着重要作用。血型鑑定是一种快速简便的方法,用于确认献血者(blood donors)和受血者(blood recipients)的相容性,避免并发症的发生。对于孕妇来说,如果血型不匹配,可能会发生凝血或血块,这可能是致命的,所以这项检查非常重要。
根据 Sarah Megginson 发表的一篇文章,89% 的澳大利亚成年人每年都会参加体育运动,62% 的人每週参加 3 次或更多次。因此,此类事件将有助于增加对血库部门的需求。血液传播疾病的负担在过去几年也有所增加,加上输血感染和手术的增加、献血意识的提高以及与献血相关的多项政府举措。
市场动态
促进者
紧急情况、交通事故和伤害的数量增加
交通事故、紧急情况、需要输血的外伤病例的增加以及怀孕期间对血液分组的需求正在推动市场增长。产前检测对血型分型的需求不断增长,血型在法医学中的应用不断增加,以及输血的严格监管标准也在推动全球血型市场的增长。
阻碍因素
缺乏基础设施和训练有素的人力资源
缺乏基础设施和训练有素的人员可能会导致抽样和测试过程中出现笔误和技术问题。红细胞和血浆的固有问题也可能导致 ABO 差异。此外,抗A和抗B抗体的低效价会导致假阳性和假阴性,阻碍市场。
机会
安全献血
血型分析有助于识别血型,并有助于了解血液是否适合输给他人。否则,他们可能会感染捐献者所患的疾病和病症,其中一些会因输血而危及生命,例如 HIV 和 AIDS。因此,这项血型检测是输血的必要因素,也是带动市场的大好机会。
威胁
由于缺乏卫生管理而传播传染病
血型不仅用于检测和鑑定血型,还用于检测传染病、诊断自身免疫性疾病和诊断某些疾病。快速抗原检测适用于在医疗机构和非工作时间服务等护理环境中诊断传染病。它直接检测抗原的存在与否。HIV抗原是有用的,因为p24抗原在感染后上升很快,比抗体快,而且由于血型检测场所卫生条件差,存在输血感染的可能,阻碍了市场增长。
COVID-19 的影响
COVID-19 流行病减少了这些诊断的使用,导致输血和献血、製造和供应链问题以及就诊次数减少。另一方面,此后对血型诊断的需求增加了。免疫系统较弱的人经常因 COVID-19 住院,并需要为 COVID-19 输血。因此,在 COVID-19 大流行后时期,对血型的需求有所增加。
基于 pcr 和微阵列技术的细分市场预计将在预测期内成为最大的细分市场
由于可以一步筛选许多基因、高灵敏度、高量化和需要多达 1000 倍的 RNA 的理念特性,基于 pcr 的和微阵列技术部分估计具有有利可图的增长。这两种技术可实现相对、准确、可重现且一致的 mRNA 分子定量。该技术使同时检查数千个基因的表达成为可能。
抗原分型部分预计在预测期内表现出最高的复合年增长率
抗原分型部分预计在预测期内表现出最快的 CAGR 增长,因为它用于识别红细胞上的特定抗原。鑑定父亲的特定红细胞抗原可能有助于评估新生儿溶血病的风险,可能有助于获得表型匹配的单位以搜索稀有血型,并可能有助于抗原储存。增加位置的可信度反过来会有助于促进血型市场的增长。
市场占有率最高的地区
由于有利的补偿政策、该地区慢性病发病率的增加以及慢性病发病率上升,亚太地区预计在预测期内将占据最大的市场份额,其中许多需要确定血型才能进行有效治疗,需要立即输血的创伤和事故受害者激增正在推动该地区的市场增长。
复合年增长率最高的地区
预计北美在预测期内的复合年增长率最高。交通事故数量的增加和慢性病患病率的上升是推动市场增长的主要因素,而交通死亡和车祸的增加增加了对血型的需求。因此,预计在预测期内对血型市场的需求将会增加。
重大发展
2022年4月,全球血浆衍生药物先驱Grifols宣布收购天成(德国)Pharmaceutical Holdings AG 100%股权。Grifols已完成对Tiancheng(Germany)Pharmaceutical Holdings AG 旗下的 Biotest AG 的收购。
2022 年 3 月,Immucor 宣布移植诊断领域的新创新这一新软件产品使 MIA FORA NGS MFlex HLA 分型检测的用户能够体验更快、更轻鬆的 NGS 分析。除了当前的 Linux 服务器之外,MIA FORA NGS EXPRESS 还为用户提供标准 Windows 桌面计算系统的成本节约选项。
2022 年 2 月,Grifols 宣布与 Endpoint Health 合作。此次合作将有助于扩大血型产品组合。
本报告内容
免费定制服务
订阅此报告的客户将免费获得以下自定义选项之一。
According to Stratistics MRC, the Global Blood Group Typing Market is accounted for $1.80 billion in 2022 and is expected to reach $3.47 billion by 2028 growing at a CAGR of 11.5% during the forecast period. Blood typing is a method of telling what type of blood a person has. Blood typing is done so one can safely donate their blood or receive a blood transfusion. It is also done to see if one has substance called Rh factor on the surface of red blood cells. Blood typing plays a crucial role in blood transfusion and donations. It is a fast and easy method used to make sure that the donor and recipient are compatible to avoid any complications. It is very critical in pregnant women as mismatched blood transfusion can result in agglutination or blood clumping, which is essentially fatal.
According to the article published by Sarah Megginson, 89% of Australian adults participate in sports every year, with 62% participating at least three times a week. Hence, these cases of accidents will contribute to the increasing demand for the blood banks segment. In addition, in the past few years, the burden of blood-borne diseases has also increased, coupled with the increasing prevalence of transfusion transmissible infection and surgeries, growing awareness about blood donation, and several government initiatives associated with blood donation.
Market Dynamics:
Driver:
Increasing in the number of emergencies, road accidents and trauma cases
An increasing number of road accidents, emergencies, and trauma cases requiring blood transfusions, and the need for grouping of the blood in pregnancy are driving the growth of the market. Growing demand for blood group typing in prenatal testing, rising usage of blood group typing in forensic sciences and strict governing standards for blood transfusion is also boosting the global blood group typing market growth.
Restraint:
Lack of infrastructure and trained personnel
Due to Lack of infrastructure and trained personnel there might be clerical errors or technical problems with a sample or during testing. Intrinsic problems within red cells or plasma may also lead to ABO discrepancies. The test cannot be conducted for weakly or rarely reactive antigens from which the results are difficult to interpret, and additionally, a low titer of anti-A or anti-B could lead to false positive or false negative results hampering the market.
Opportunity:
Safe donation
Blood group typing helps us in identifying the blood group and helps to know the compatibility of the blood when transfused to another person, if not there are chances of getting infected with diseases or the condition that the donor has, some of the blood transfused diseases are HIV, AIDS etc. which are life threatening. Hence as this blood group typing is a necessary element in blood transfusion there are greater opportunities of driving the market.
Threat:
Transmission of infectious disease due to lack of hygiene
The blood group typing is done not only to detect or identify the blood group but also to detect infections, diagnose autoimmune disorders, as well as to diagnose certain diseased conditions the rapid antigen test is suitable for diagnosing infections in care settings, like GP surgeries and out-of-hours services. It directly detects the presence or absence of an antigen. HIV antigen is useful because the p24 antigen rises soon after infection and sooner than antibodies thus this can also lead to transfusion of infection due to lack of hygiene at the premises of blood group typing and thus hinders the market growth.
COVID-19 Impact
The COVID-19 pandemic has resulted in a decline in the number of the blood transfusions and donations, manufacturing and supply chain issues, and a decrease in the number of the visits to healthcare facilities leading to reduced usage of these diagnostic products. On the other hand the demand for blood group typing has increased subsequently. Many individuals with weak immune systems have been infected by COVID-19 and hospitalized and may require a blood transfusion due to COVID-19. As a result, the demand for blood group typing has risen during COVID-19, following the pandemic..
The pcr-based & microarray techniques segment is expected to be the largest during the forecast period
The pcr-based & microarray techniques segment is estimated to have a lucrative growth, due to its idea property to screen a lot of genes in one step and is very sensitive, highly quantitative and requires up to 1000-fold less RNA. Both allow a relative and accurate quantification of mRNA molecules with a sufficiently high repeatability and low variability. This technique makes it possible to examine the expression of thousands of genes simultaneously.
The antigen typing segment is expected to have the highest CAGR during the forecast period
The antigen typing segment is anticipated to witness the fastest CAGR growth during the forecast period, due to its use in identifying specific antigens on the red cell. Identification of specific red cell antigens of the father may be useful in assessing the risk of haemolytic disease of the newborn, which helps in obtaining phenotypically compatible units to search for rare blood types and to increase the reliability of repositories of antigen which in turn helps in booting the growth of the blood group typing market.
Region with highest share:
Asia Pacific is projected to hold the largest market share during the forecast period owing to the availability of favourable compensation policies and increasing occurrence of chronic disorders in this region and escalating incidence of chronic diseases, many of which require blood type determination for effective treatment and surging number of trauma and accident victims, who require instant blood transfusion are driving the market growth in this region.
Region with highest CAGR:
North America is projected to have the highest CAGR over the forecast period, owing to increase in the number of road accidents and the rising prevalence of chronic diseases are the major factors driving the growth of the market the increasing road fatalities and crashes are increasing the demand for blood group typing. This is expected to augment the demand for the blood group typing market over the forecast period.
Key players in the market
Some of the key players profiled in the Blood Group Typing Market include Quotient Limited, DIAGAST, Grifols, S.A, Immucor, Inc, CareDX Inc., Agena Bioscience.Inc., Bio-Rad Laboratories Inc, Thermo Fisher Scientific Inc, Merck KGaA, Beckman Coulter, Inc., QIAGEN, BAG Health Care GmbH
Key Developments:
In April 2022, Grifols, a global pioneer in plasma-derived pharmaceuticals, announced its acquisition of Tiancheng (Germany) Pharmaceutical Holdings AG's 100% share capital. Grifols' completed the acquisition of Biotest AG, which is owned by Tiancheng (Germany) Pharmaceutical Holdings AG.
In March 2022, Immucor Announces New Innovations in Transplant Diagnostics This new software offering gives users of MIA FORA NGS MFlex HLA Typing assays a faster and easier NGS analysis experience. MIA FORA NGS EXPRESS will also allow users the cost-saving option of a standard Windows desktop computing system in addition to the current Linux server.
In February 2022, Grifols announced collaboration with Endpoint Health, Inc. This collaboration would help in the expansion of the product portfolio for blood group typing.
Products Covered:
Techniques Covered:
Test Types Covered:
End Users Covered:
Regions Covered:
What our report offers:
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options: